Variegate Porphyria Clinical Trial
Official title:
Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)-Related Skin Disease.
The primary objective is to evaluate the impact of afamelanotide on the severity of skin disease in patients with Variegate Porphyria (VP). The secondary objectives are to evaluate the safety and tolerability of afamelanotide in patients with VP and evaluate the impact of afamelanotide on the quality of life of patients with VP.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02922413 -
Panhematin for Prevention of Acute Attacks of Porphyria
|
Phase 2 | |
Active, not recruiting |
NCT02935400 -
Acute Porphyria Biomarkers for Disease Activity
|